Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625503 · ClinicalTrials.gov registry record · Early Phase 1
Dilution of Verapamil During Intraarterial Administration
A Early Phase 1 study of Pain and Vasospasm;Peripheral, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05625503: Completed Early Phase 1 study of Pain and Vasospasm;Peripheral, sponsored by University of Illinois at Chicago.
NCT05625503 is a Early Phase 1 study of Pain and Vasospasm;Peripheral that has completed, run by University of Illinois at Chicago. The registered enrollment target is 55 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05625503, a Early Phase 1 study of Pain and Vasospasm;Peripheral, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a randomized, single-blind, prospective trial designed to evaluate the efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary angiography. Patients who are 18 years or older and undergoing non-emergent percutaneous coronary angiography via TRA will be included. Patients who are non-English speaking, pregnant, or intubated will be excluded. Patients will be randomized to one of the two following groups: 1. Group 1 will receive IA Verapamil 5 mg (2mL) diluted with 8 mL of normal saline 2. Group 2 will receive IA Nicardipine 400 mcg (undiluted, 8 mL) The investigators will document the patient's level of discomfort on the Visual Analogue Scale 30 seconds before and after administration of IA Verapamil/Nicardipine. The investigators will also document the presence of radial artery spasms.
Primary Outcome
The investigators will document the presence or absence of radial artery spasms with either 0,1, or 2. 0 will indicate no radial artery spasms. 1 will indicate radial artery spasms that did not require a change in strategy. 2 will indicate radial artery spasms that required a change in strategy such as alternate access.
Conditions Studied
Interventions
- DRUG Verapamil
- DRUG Nicardipine
Study Locations (1)
Illinois
- University of Illinois Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2023-12-01 |
| Phase | Early Phase 1 |
What the finished NCT05625503 record still lists
NCT05625503 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Verapamil is the first listed.
NCT05625503 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05625503 about?
NCT05625503 is a clinical study titled "Dilution of Verapamil During Intraarterial Administration". This study will be a randomized, single-blind, prospective trial designed to evaluate the efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary angiography. Patients who are 18 ye...
What is the current status of trial NCT05625503?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 55 participants. The study started on 2022-12-13. Estimated completion is 2023-12-01.
What conditions does trial NCT05625503 study?
This clinical trial studies the following conditions: Pain, Vasospasm;Peripheral, Burning.
What interventions are being tested in trial NCT05625503?
The interventions under investigation include: Verapamil (DRUG), Nicardipine (DRUG).
Who is sponsoring clinical trial NCT05625503?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05625503 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05625503's enrollment target sits among peer trials
55 249th of 374 higher than 126 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination
RECRUITING · Early Phase 1
-
The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults
RECRUITING · Early Phase 1
-
Effects of Dronabinol in Opioid Maintained Patients
RECRUITING · Early Phase 1
-
Remimazolam NeuroImaging
RECRUITING · Early Phase 1
-
Nitrous Oxide Neuroimaging
RECRUITING · Early Phase 1
-
Ketamine and Propofol NeuroImaging
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI